Login to Your Account



Already Hot HCV Market on Fire with $2.5B Inhibitex Buy

By Catherine Shaffer
BioWorld Today Contributing Writer

Tuesday, January 10, 2012
If any doubt remained regarding the potential of nucleoside analogue drugs to treat hepatitis C virus, the $2.5 billion offer for Inhibitex Inc. by Bristol-Myers Squibb Co. should have put it to rest. Closely following Gilead Sciences Inc.'s acquisition of a similar technology in its $11 billion purchase of Pharmasset Inc., the deal makes it clear that a nuc is now a must-have weapon in the HCV arsenal.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription